Shidlovski / Shutterstock.com
Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
As compound patents and regulatory data protection for medicinal products expire, pharmaceutical companies increasingly look to develop new uses for their products. This strategy usually involves filing second medical use patents to protect the invention and research investment.
As well as the complex patent landscape that surrounds such patents, and any extension to regulatory marketing protection that may be available, several regulatory and practical factors may impact how well second uses for existing products can be protected from immediate generic competition.
When assessing a generic medicinal product, the competent authorities generally require the same information to appear in the summary of product characteristics (SmPC) and other product information of the generic medicine, as for the original, reference medicine.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Arnold & Porter, second medical use, patent holders, data protection, generics, SmPC, INN, CJEU, healthcare, pharmaceuticals, English High Court